Sequential Administration of TrenibotulinumtoxinE and OnabotulinumtoxinA for Glabellar Lines: a Phase 1 Evaluation

Clicks: 9
ID: 337406
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #123 of 129 articles by views in Aesthetic surgery journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 129 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Botulinum neurotoxin type A (BoNT/A) is widely used to treat facial wrinkles. Certain individuals considering neurotoxin treatments may hesitate to try BoNT/A products due to uncertain outcomes. TrenibotulinumtoxinE (trenibotE), a botulinum neurotoxin serotype E, has a distinct pharmacological profile from BoNT/A. Objectives This Phase 1 study evaluated the safety and efficacy of sequential administration of trenibotE followed by onabotulinumtoxinA (onabotA) for the treatment of moderate-to-severe glabellar lines (GL). Methods Participants received a single administration of placebo or trenibotE 700 U on Day 1. On Day 30, eligible participants received a single administration of onabotA 20 U and were followed through Day 150. Investigators and participants utilized the Facial Wrinkle Scale (FWS) to assess GL at maximum frown during each visit. The primary endpoint was investigator-assessed achievement of None or Mild on the FWS at maximum frown at Day 60. Safety and immunogenicity were evaluated. Results On Day 1, 90 participants received placebo or trenibotE. On Day 30, 85 participants received onabotA. Responder rates at Day 60 were similar between participants who initially received placebo or trenibotE. Peak responder rates of None or Mild GL severity were similar for trenibotE at Day 7 and onabotA at Day 60 (30 days post-onabotA). Most treatment-emergent adverse events were mild, nonserious, and unrelated to study treatment. No participants developed treatment-emergent binding or neutralizing antibodies to trenibotE or onabotA. Conclusions Sequential administration of trenibotE followed by onabotA as studied identified no new safety concerns and may be a potential treatment strategy for moderate-to-severe GL. Plain-Text Summary In this study, treatment with fast-acting trenibotulinumtoxinE followed 30 days later by onabotulinumtoxinA generally improved facial wrinkles (glabellar lines), as assessed by both patients and clinicians. No new safety concerns were identified. Level of Evidence: 1 (Therapeutic)
Reference Key
openalex_W7223952568 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Joely A. Kaufman-Janette, C. William Hanke, David Wirta, Steve Dayan, Sabrina Guillen Fabi, Amy Forman Taub, Leslie Baumann, Craig F. Teller, Joel L. Cohen, Grace West, Amy S. Weitzenfeld, Jie Shen, Stephanie Manson Brown, Mitchell F. Brin, Mitalee Tamhane
Are you one of these authors? Claim your profile
Journal Aesthetic surgery journal
Year 2026
DOI
10.1093/asj/sjag205
URL
https://doi.org/10.1093/asj/sjag205
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.